Resource Center
In this episode of the Eurofins Viracor podcast listen to our Transplant Radio interview series part 2 from ATC 2022 in Boston. We exhibited as Eurofins Transplant, which is comprised of Eurofins Viracor, Eurofins Transplant Genomics, Eurofins Donor & Product Testing (DPT), Eurofins Ascend Clinical and Eurofins CellTx.
This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.